Our mission is to save lives through early noninvasive cancer detection and to become the world's leading breath-based diagnostics company. Our lung cancer test is scheduled to launch commercially Q2 2024. We will initially operate through CLIA Labs, urgent care centers, and therapeutic infusion centers in the United States.